Ginkgo Bioworks (NYSE:DNA) Director Christian Henry Sells 5,000 Shares of Stock

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Director Christian Henry sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $7.08, for a total value of $35,400.00. Following the sale, the director owned 19,310 shares of the company’s stock, valued at $136,714.80. The trade was a 20.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Ginkgo Bioworks Price Performance

NYSE:DNA opened at $7.04 on Thursday. The stock has a market cap of $474.41 million, a PE ratio of -1.41 and a beta of 1.76. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $5.37 and a fifty-two week high of $17.58. The stock’s 50-day moving average is $7.63 and its two-hundred day moving average is $7.87.

Ginkgo Bioworks (NYSE:DNA) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.15. The business had revenue of $20.16 million during the quarter, compared to analyst estimates of $24.05 million. Ginkgo Bioworks had a negative net margin of 259.96% and a negative return on equity of 60.27%. On average, equities research analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -3.2 earnings per share for the current year.

Institutional Trading of Ginkgo Bioworks

Large investors have recently added to or reduced their stakes in the business. Prescott Group Capital Management L.L.C. acquired a new stake in shares of Ginkgo Bioworks in the 4th quarter valued at $4,503,000. UBS Group AG increased its position in Ginkgo Bioworks by 86.4% during the fourth quarter. UBS Group AG now owns 489,418 shares of the company’s stock worth $4,067,000 after buying an additional 226,861 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in Ginkgo Bioworks by 28,457.3% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 228,744 shares of the company’s stock valued at $1,901,000 after buying an additional 227,943 shares in the last quarter. Balance Capital Partners L.P. bought a new position in Ginkgo Bioworks during the second quarter valued at about $1,972,179. Finally, Dimensional Fund Advisors LP lifted its position in shares of Ginkgo Bioworks by 23.8% in the first quarter. Dimensional Fund Advisors LP now owns 127,048 shares of the company’s stock worth $779,000 after buying an additional 24,434 shares during the last quarter. 78.63% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Zacks Research upgraded shares of Ginkgo Bioworks to a “hold” rating in a report on Monday, August 17th. Oppenheimer set a $5.00 price objective on Ginkgo Bioworks in a report on Wednesday, September 9th. BTIG Research reissued a “sell” rating and set a $5.00 price objective on shares of Ginkgo Bioworks in a research report on Friday, September 4th. TD Cowen downgraded Ginkgo Bioworks from a “buy” rating to a “hold” rating and lowered their target price for the company from $12.00 to $9.00 in a research note on Friday, August 7th. Finally, Wall Street Zen lowered Ginkgo Bioworks from a “hold” rating to a “sell” rating in a research report on Saturday, September 5th. Two investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus target price of $6.33.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks is a biotechnology company that develops and operates a platform for programming cells. Its technology combines biological engineering, automation, software and data science to help customers design, build and test microorganisms and other biological systems for commercial applications.

The company provides cell-programming services and related tools to customers in areas including pharmaceuticals, agriculture, food and ingredients, industrial chemicals, materials and consumer products.